EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE
Clinical trials for EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE trials appear
Sign up with your email to follow new studies for EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…
Matched conditions: EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for lymphoma patients: experimental drug epcoritamab enters phase 2 trial
Disease control Recruiting nowThis study tests whether the investigational drug epcoritamab can help people with newly diagnosed marginal zone lymphoma, a slow-growing blood cancer. About 25 adults will receive the drug and be monitored for complete remission after 12 cycles. The goal is to see if this treatm…
Matched conditions: EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE
Phase: PHASE2 • Sponsor: Izidore Lossos, MD • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC